Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Myriad Genetics (MYGN) Non-cash Items (2016 - 2019)

Myriad Genetics has reported Non-cash Items over the past 11 years, most recently at $4.8 million for Q1 2020.

Quarterly Non-cash Items fell 12.73% to $4.8 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Mar 2020, down 12.73% year-over-year, with the annual reading at $5.5 million for FY2019, N/A changed from the prior year.
Non-cash Items was $4.8 million for Q1 2020 at Myriad Genetics, down from $4.9 million in the prior quarter.
Over five years, Non-cash Items peaked at $8.6 million in Q1 2016 and troughed at $2.2 million in Q1 2017.
The 5-year median for Non-cash Items is $6.5 million (2016), against an average of $6.2 million.
Year-over-year, Non-cash Items plummeted 74.42% in 2017 and then surged 218.18% in 2018.
A 5-year view of Non-cash Items shows it stood at $7.6 million in 2016, then decreased by 2.63% to $7.4 million in 2017, then fell by 24.32% to $5.6 million in 2018, then fell by 12.5% to $4.9 million in 2019, then decreased by 2.04% to $4.8 million in 2020.
Per Business Quant, the three most recent readings for MYGN's Non-cash Items are $4.8 million (Q1 2020), $4.9 million (Q4 2019), and $5.0 million (Q3 2019).